Chemotherapy-induced nausea and vomiting (CINV) is one of the most feared side effects experienced by patients with cancer. The precise physiologic mechanisms responsible for acute and delayed CINV continue to be elucidated and have provided an opportunity to develop antiemetic therapies targeting these pathways.Drugs used in the treatment of chemotherapy-induced nausea and vomiting (CINV) Aloxi (palonosetron hydrochloride) Emend (aprepitant) Kytril tablets (granisetron) Maxolon (metoclopramide hydrochloride)
We aims to provide a complete knowledgeable report so that the readers will benefit from it. The report is properly examined and compiled by industry experts and will shed light on the key information that requires from the clients.
Case numbers are resurging in parts of the world where the COVID-19 pandemic was waning, falling in places that saw huge surges recently, and just beginning to rise in previously little-impacted parts of the globe.
Studying and analyzing the impact of Coronavirus COVID-19 on the CINV Existing and Pipeline Drugs industry, the report provide in-depth analysis and professtional advices on how to face the post COIVD-19 period.
Market Segment by Product Type
Aloxi (palonosetron)
Zofran Generic (ondansetron)
Kytril Generic (granisetron)
Emend (aprepitant)
Akynzeo (netupitant-palonosetron)
SUSTOL (extended release granisetron injection)
Rolapitant
Market Segment by Product Application
Hospitals
Specialty Clinics
Diagnostic Centers Therapeutics
Hospital Pharmacies
Drugstores
Finally, the report provides detailed profile and data information analysis of leading company.
GlaxoSmithKline
Helsinn
Heron Therapeutics
Merck
Tesaro
Insights and Tools:
Projected and forecast revenue values are in constant U.S. dollars, unadjusted for inflation.
Product values and regional markets are estimated by market analyst, data analyst and people from related industry, based on companys' revenue and applications market respectively.
The data sources include but not limited to reports of companys,international organizations and governments, MMI market surveys,and related industry news.
Analyses of global market trends, with historical data, estimates for 2022 and projections of compound annual growth rates (CAGRs) through 2027
The market research includes historical and forecast data from like demand, application details, price trends, and company shares by geography, especially focuses on the key regions like United States, European Union, China, and other regions.
In addition, the report provides insight into main drivers,challenges,opportunities and risk of the market and strategies of suppliers. Key players are profiled as well with their market shares in the global market discussed.
Research Objectives
1.To study and analyze the global CINV Existing and Pipeline Drugs consumption (value) by key regions/countries, product type and application, history data from 2017 to 2021, and forecast to 2027.
2.To understand the structure of CINV Existing and Pipeline Drugs market by identifying its various subsegments.
3.Focuses on the key global CINV Existing and Pipeline Drugs manufacturers, to define, describe and analyze the value, market share, market competition landscape, Porter's five forces analysis, SWOT analysis and development plans in next few years.
4.To analyze the CINV Existing and Pipeline Drugs with respect to individual growth trends, future prospects, and their contribution to the total market.
5.To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
6.To project the consumption of CINV Existing and Pipeline Drugs submarkets, with respect to key regions (along with their respective key countries).
7.To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
8.To strategically profile the key players and comprehensively analyze their growth strategies.
Table of Contents
Global CINV Existing and Pipeline Drugs Market Research Report 2022, Forecast to 2027
1 Market Study Overview
1.1 Study Objectives
1.2 CINV Existing and Pipeline Drugs Introduce
1.3 Combined with the Analysis of Macroeconomic Indicators
1.4 Brief Description of Research methods
1.5 Market Breakdown and Data Triangulation
2 Global Trend Summary
2.1 CINV Existing and Pipeline Drugs Segment by Type
2.1.1 Aloxi (palonosetron)
2.1.2 Zofran Generic (ondansetron)
2.1.3 Kytril Generic (granisetron)
2.1.4 Emend (aprepitant)
2.1.5 Akynzeo (netupitant-palonosetron)
2.1.6 SUSTOL (extended release granisetron injection)
2.1.7 Rolapitant
2.2 Market Analysis by Application
2.2.1 Hospitals
2.2.2 Specialty Clinics
2.2.3 Diagnostic Centers Therapeutics
2.2.4 Hospital Pharmacies
2.2.5 Drugstores
2.3 Global CINV Existing and Pipeline Drugs Market Comparison by Regions (2017-2027)
2.3.1 Global CINV Existing and Pipeline Drugs Market Size (2017-2027)
2.3.2 North America CINV Existing and Pipeline Drugs Status and Prospect (2017-2027)
2.3.3 Europe CINV Existing and Pipeline Drugs Status and Prospect (2017-2027)
2.3.4 China CINV Existing and Pipeline Drugs Status and Prospect (2017-2027)
2.3.5 Japan CINV Existing and Pipeline Drugs Status and Prospect (2017-2027)
2.3.6 Southeast Asia CINV Existing and Pipeline Drugs Status and Prospect (2017-2027)
2.4 Basic Product Information
2.4.1 Basic Product Information & Technology Development History
2.4.2 Product Manufacturing Process
2.4.3 Interview with Major Market Participants
2.4.4 High-end Market Analysis and Forecast
2.5 Coronavirus Disease 2019 (Covid-19): CINV Existing and Pipeline Drugs Industry Impact
2.5.1 CINV Existing and Pipeline Drugs Business Impact Assessment - Covid-19
2.5.2 Market Trends and CINV Existing and Pipeline Drugs Potential Opportunities in the COVID-19 Landscape
2.5.3 Measures / Proposal against Covid-19
3 Competition by Manufacturer
3.1 Global CINV Existing and Pipeline Drugs Sales and Market Share by Manufacturer (2017-2022)
3.2 Global CINV Existing and Pipeline Drugs Revenue and Market Share by Manufacturer (2017-2022)
3.3 Global CINV Existing and Pipeline Drugs Industry Concentration Ratio (CR5 and HHI)
3.4 Top 5 CINV Existing and Pipeline Drugs Manufacturer Market Share
3.5 Top 10 CINV Existing and Pipeline Drugs Manufacturer Market Share
3.6 Date of Key Manufacturers Enter into CINV Existing and Pipeline Drugs Market
3.7 Key Manufacturers CINV Existing and Pipeline Drugs Key Manufacturers
3.8 Mergers & Acquisitions Planning
4 Analysis of CINV Existing and Pipeline Drugs Industry Key Manufacturers
4.1 GlaxoSmithKline
4.1.1 Compan Detail
4.1.2 GlaxoSmithKline CINV Existing and Pipeline Drugs Product Introduction, Application and Specification
4.1.3 GlaxoSmithKline 131 Sales, Price, Cost, Gross Margin, and Revenue (2017-2022)
4.1.4 Main Business Overview
4.1.5 GlaxoSmithKline News
4.2 Helsinn
4.2.1 Compan Detail
4.2.2 Helsinn CINV Existing and Pipeline Drugs Product Introduction, Application and Specification
4.2.3 Helsinn CINV Existing and Pipeline Drugs Sales, Price, Cost, Gross Margin, and Revenue (2017-2022)
4.2.4 Main Business Overview
4.2.5 GlaxoSmithKline News
4.3 Heron Therapeutics
4.3.1 Compan Detail
4.3.2 Heron Therapeutics CINV Existing and Pipeline Drugs Product Introduction, Application and Specification
4.3.3 Heron Therapeutics CINV Existing and Pipeline Drugs Sales, Price, Cost, Gross Margin, and Revenue (2017-2022)
4.3.4 Main Business Overview
4.3.5 Heron Therapeutics News
4.4 Merck
4.4.1 Compan Detail
4.4.2 Merck CINV Existing and Pipeline Drugs Product Introduction, Application and Specification
4.4.3 Merck CINV Existing and Pipeline Drugs Sales, Price, Cost, Gross Margin, and Revenue (2017-2022)
4.4.4 Main Business Overview
4.4.5 Merck News
4.5 Tesaro
4.5.1 Compan Detail
4.5.2 Merck CINV Existing and Pipeline Drugs Product Introduction, Application and Specification
4.5.3 Tesaro CINV Existing and Pipeline Drugs Sales, Price, Cost, Gross Margin, and Revenue (2017-2022)
4.5.4 Main Business Overview
4.5.5 Tesaro News
5 Global CINV Existing and Pipeline Drugs Market Segment by Big Type
5.1 Global CINV Existing and Pipeline Drugs Revenue, Sales and Market Share by Big Type (2017-2022)
5.1.1 Global CINV Existing and Pipeline Drugs Sales and Market Share by Big Type (2017-2022)
5.1.2 Global CINV Existing and Pipeline Drugs Revenue and Market Share by Big Type (2017-2022)
5.2 Aloxi (palonosetron) Sales Growth Rate and Price
5.2.1 Global Aloxi (palonosetron) Sales Growth Rate (2017-2022)
5.2.2 Global Aloxi (palonosetron) Price (2017-2022)
5.3 Zofran Generic (ondansetron) Sales Growth Rate and Price
5.3.1 Global Zofran Generic (ondansetron) Sales Growth Rate (2017-2022)
5.3.2 Global Zofran Generic (ondansetron) Price (2017-2022)
5.4 Kytril Generic (granisetron) Sales Growth Rate and Price
5.4.1 Global Kytril Generic (granisetron) Sales Growth Rate (2017-2022)
5.4.2 Global Kytril Generic (granisetron) Price (2017-2022)
5.5 Emend (aprepitant) Sales Growth Rate and Price
5.5.1 Global Emend (aprepitant) Sales Growth Rate (2017-2022)
5.5.2 Global Emend (aprepitant) Price (2017-2022)
5.6 Akynzeo (netupitant-palonosetron) Sales Growth Rate and Price
5.6.1 Global Akynzeo (netupitant-palonosetron) Sales Growth Rate (2017-2022)
5.6.2 Global Akynzeo (netupitant-palonosetron) Price (2017-2022)
5.7 SUSTOL (extended release granisetron injection) Sales Growth Rate and Price
5.7.1 Global SUSTOL (extended release granisetron injection) Sales Growth Rate (2017-2022)
5.7.2 Global SUSTOL (extended release granisetron injection) Price (2017-2022)
5.8 Rolapitant Sales Growth Rate and Price
5.8.1 Global Rolapitant Sales Growth Rate (2017-2022)
5.8.2 Global Rolapitant Price (2017-2022)
6 Global CINV Existing and Pipeline Drugs Market Segment by Big Application
6.1 Global CINV Existing and Pipeline Drugs Sales Market Share by Big Application (2017-2022)
6.2 Hospitals Sales Growth Rate (2017-2022)
6.3 Specialty Clinics Sales Growth Rate (2017-2022)
6.4 Diagnostic Centers Therapeutics Sales Growth Rate (2017-2022)
6.5 Hospital Pharmacies Sales Growth Rate (2017-2022)
6.6 Drugstores Sales Growth Rate (2017-2022)
7 Global CINV Existing and Pipeline Drugs Forecast
7.1 Global CINV Existing and Pipeline Drugs Revenue, Sales and Growth Rate (2022-2027)
7.2 CINV Existing and Pipeline Drugs Market Forecast by Regions (2022-2027)
7.2.1 North America CINV Existing and Pipeline Drugs Market Forecast (2022-2027)
7.2.2 Europe CINV Existing and Pipeline Drugs Market Forecast (2022-2027)
7.2.3 China CINV Existing and Pipeline Drugs Market Forecast (2022-2027)
7.2.4 Japan CINV Existing and Pipeline Drugs Market Forecast (2022-2027)
7.2.5 Southeast Asia CINV Existing and Pipeline Drugs Market Forecast (2022-2027)
7.2.6 Other Regions CINV Existing and Pipeline Drugs Market Forecast (2022-2027)
7.3 CINV Existing and Pipeline Drugs Market Forecast by Type (2022-2027)
7.3.1 Global CINV Existing and Pipeline Drugs Sales Forecast by Type (2022-2027)
7.3.2 Global CINV Existing and Pipeline Drugs Market Share Forecast by Type (2022-2027)
7.4 CINV Existing and Pipeline Drugs Market Forecast by Application (2022-2027)
7.4.1 Global CINV Existing and Pipeline Drugs Sales Forecast by Application (2022-2027)
7.4.2 Global CINV Existing and Pipeline Drugs Market Share Forecast by Application (2022-2027)
8 Market Analysis
8.1.1 Market Overview
8.1.2 Market Opportunities
8.1.3 Market Risk
8.1.4 Market Driving Force
8.1.5 Porter's Five Forces Analysis
8.1.6 SWOT Analysis
9 CINV Existing and Pipeline Drugs Related Market Analysis
9.1 Upstream Analysis
9.1.1 Macro Analysis of Upstream Markets
9.1.2 Key Players in Upstream Markets
9.1.3 Upstream Market Trend Analysis
9.1.4 CINV Existing and Pipeline Drugs Manufacturing Cost Analysis
9.2 Downstream Market Analysis
9.2.1 Macro Analysis of Down Markets
9.2.2 Key Players in Down Markets
9.2.3 Downstream Market Trend Analysis
9.2.4 Sales Channel, Distributors, Traders and Dealers
10 Research Findings and Conclusion
List of Tables and Figures
Figure Product Picture CINV Existing and Pipeline Drugs
Figure Market Concentration Ratio and Market Maturity Analysis of CINV Existing and Pipeline Drugs
Figure Bottom-up and Top-down Approaches for This Report
Figure Part of Our External Database
Figure Part of Our External Database
Figure Key Executives Interviewed
Table Global CINV Existing and Pipeline Drugs Market Size by Big Type
Figure Global Market Share of CINV Existing and Pipeline Drugs by Big Type in 2021
Figure Aloxi (palonosetron) Picture (2017-2022)
Figure Zofran Generic (ondansetron) Picture (2017-2022)
Figure Kytril Generic (granisetron) Picture (2017-2022)
Figure Emend (aprepitant) Picture (2017-2022)
Figure Akynzeo (netupitant-palonosetron) Picture (2017-2022)
Figure SUSTOL (extended release granisetron injection) Picture (2017-2022)
Global CINV Existing and Pipeline Drugs Market Size by Big Application
Table Global CINV Existing and Pipeline Drugs Market Size by Application
Figure Global CINV Existing and Pipeline Drugs Market Share by Big Application in 2021
Figure Hospitals Picture
Figure Specialty Clinics Picture
Figure Diagnostic Centers Therapeutics Picture
Figure Hospital Pharmacies Picture
Figure Drugstores Picture
Table Global CINV Existing and Pipeline Drugs Comparison by Regions (M USD) (2017-2027)
Figure Global CINV Existing and Pipeline Drugs Market Size (Million US$) (2017-2027)
Figure North America CINV Existing and Pipeline Drugs Revenue (Million US$) Growth Rate (2017-2027)
Figure Europe CINV Existing and Pipeline Drugs Revenue (Million US$) Growth Rate (2017-2027)
Figure China CINV Existing and Pipeline Drugs Revenue (Million US$) Growth Rate (2017-2027)
Figure Japan CINV Existing and Pipeline Drugs Revenue (Million US$) Growth Rate (2017-2027)
Figure Southeast Asia CINV Existing and Pipeline Drugs Revenue (Million US$) Growth Rate (2017-2027)
Table Business Impact Assessment - Covid-19
Table Market Trends and CINV Existing and Pipeline Drugs Potential Opportunities in the COVID-19 Landscape
Table Measures / Proposal against Covid-19
Table Global CINV Existing and Pipeline Drugs Sales by Manufacturer (2017-2022)
Figure Global CINV Existing and Pipeline Drugs Sales Market Share by Manufacturer in 2021
Table Global CINV Existing and Pipeline Drugs Revenue by Manufacturer (2017-2022)
Figure Global CINV Existing and Pipeline Drugs Revenue Market Share by Manufacturer in 2021
Table Global CINV Existing and Pipeline Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
Figure Top 5 CINV Existing and Pipeline Drugs Manufacturer (Revenue) Market Share in 2021
Figure Top 10 CINV Existing and Pipeline Drugs Manufacturer (Revenue) Market Share in 2021
Table Date of Key Manufacturers Enter into CINV Existing and Pipeline Drugs Market
Table Key Manufacturers CINV Existing and Pipeline Drugs Product Type
Table Mergers & Acquisitions Planning
Table GlaxoSmithKline Company Profile
Table CINV Existing and Pipeline Drugs Product Introduction, Application and Specification of GlaxoSmithKline
Table CINV Existing and Pipeline Drugs Sales (K Unit), Price (USD/Unit), Revenue (M USD) and Gross Margin of Company One 2017-2022
Table Company One Main Business
Table Company One Recent Development
Table Helsinn Company Profile
Table CINV Existing and Pipeline Drugs Product Introduction, Application and Specification of Helsinn
Table CINV Existing and Pipeline Drugs Sales (K Unit), Price (USD/Unit), Revenue (M USD) and Gross Margin of Company Two 2017-2022
Table Helsinn Recent Development
Table Heron Therapeutics Company Profile
Table CINV Existing and Pipeline Drugs Product Introduction, Application and Specification of Heron Therapeutics
Table CINV Existing and Pipeline Drugs Sales (K Unit), Price (USD/Unit), Revenue (M USD) and Gross Margin of Company Two 2017-2022
Table Heron Therapeutics Main Business
Table Heron Therapeutics Recent Development
Table Merck Company Profile
Table CINV Existing and Pipeline Drugs Product Introduction, Application and Specification of Merck
Table CINV Existing and Pipeline Drugs Sales (K Unit), Price (USD/Unit), Revenue (M USD) and Gross Margin of Company Two 2017-2022
Table Merck Main Business
Table Merck Recent Development
Table Merck Main Business
Table Merck Recent Development
Table Tesaro Company Profile
Table CINV Existing and Pipeline Drugs Product Introduction, Application and Specification of Tesaro
Table CINV Existing and Pipeline Drugs Sales (K Unit), Price (USD/Unit), Revenue (M USD) and Gross Margin of Company Two 2017-2022
Table Tesaro Main Business
Table Tesaro Recent Development
Figure Global CINV Existing and Pipeline Drugs Sales and Growth Rate (2017-2022)
Figure Global CINV Existing and Pipeline Drugs Revenue and Growth Rate (2017-2022)
Table Global CINV Existing and Pipeline Drugs Sales by Regions (2017-2022)
Figure Global CINV Existing and Pipeline Drugs Sales Market Share by Regions in 2021
Table Global CINV Existing and Pipeline Drugs Revenue by Regions (2017-2022)
Figure Global CINV Existing and Pipeline Drugs Revenue Market Share by Regions in 2021
Figure North America CINV Existing and Pipeline Drugs Sales and Growth Rate (2017-2022)
Figure Europe CINV Existing and Pipeline Drugs Sales and Growth Rate (2017-2022)
Figure China CINV Existing and Pipeline Drugs Sales and Growth Rate (2017-2022)
Figure Japan CINV Existing and Pipeline Drugs Sales and Growth Rate (2017-2022)
Figure Southeast Asia CINV Existing and Pipeline Drugs Sales and Growth Rate (2017-2022)
Figure Other Regions CINV Existing and Pipeline Drugs Sales and Growth Rate (2017-2022)
Table Global CINV Existing and Pipeline Drugs Sales by Big Type (2017-2022)
Table Global CINV Existing and Pipeline Drugs Sales Market Share by Big Type (2017-2022)
Figure Global CINV Existing and Pipeline Drugs Sales Market Share by Big Type in 2019
Table Global CINV Existing and Pipeline Drugs Revenue by Big Type (2017-2022)
Table Global CINV Existing and Pipeline Drugs Revenue Market Share by Big Type (2017-2022)
Table Global CINV Existing and Pipeline Drugs Revenue Market Share by Big Type in 2019
Figure Global Aloxi (palonosetron) Sales Growth Rate (2017-2022)
Figure Global Aloxi (palonosetron) Price (2017-2022)
Figure Global Zofran Generic (ondansetron) Sales Growth Rate (2017-2022)
Figure Global Zofran Generic (ondansetron) Price (2017-2022)
Figure Global Kytril Generic (granisetron) Sales Growth Rate (2017-2022)
Figure Global Kytril Generic (granisetron) Price (2017-2022)
Figure Global Emend (aprepitant) Sales Growth Rate (2017-2022)
Figure Global Emend (aprepitant) Price (2017-2022)
Figure Global SUSTOL (extended release granisetron injection) Sales Growth Rate (2017-2022)
Figure Global SUSTOL (extended release granisetron injection) Price (2017-2022)
Figure Global Rolapitant Sales Growth Rate (2017-2022)
Table Global CINV Existing and Pipeline Drugs Sales by Big Application (2017-2022)
Table Global CINV Existing and Pipeline Drugs Sales Market Share by Big Application (2017-2022)
Figure Global CINV Existing and Pipeline Drugs Sales Market Share by Big Application in 2019
Figure Global Hospitals Sales Growth Rate (2017-2022)
Figure Global Specialty Clinics Sales Growth Rate (2017-2022)
Figure Global Diagnostic Centers Therapeutics Sales Growth Rate (2017-2022)
Figure Global Hospital Pharmacies Sales Growth Rate (2017-2022)
Figure Global Drugstores Sales Growth Rate (2017-2022)
Figure Global CINV Existing and Pipeline Drugs Sales and Growth Rate (2022-2027)
Figure Global CINV Existing and Pipeline Drugs Revenue and Growth Rate (2022-2027)
Table Global CINV Existing and Pipeline Drugs Sales Forecast by Regions (2022-2027)
Table Global CINV Existing and Pipeline Drugs Market Share Forecast by Regions (2022-2027)
Figure North America Sales CINV Existing and Pipeline Drugs Market Forecast (2022-2027)
Figure Europe Sales CINV Existing and Pipeline Drugs Market Forecast (2022-2027)
Figure China Sales CINV Existing and Pipeline Drugs Market Forecast (2022-2027)
Figure Japan Sales CINV Existing and Pipeline Drugs Market Forecast (2022-2027)
Figure Southeast Asia Sales CINV Existing and Pipeline Drugs Market Forecast (2022-2027)
Figure Other Regions Sales CINV Existing and Pipeline Drugs Market Forecast (2022-2027)
Table Global CINV Existing and Pipeline Drugs Sales Forecast by Type (2022-2027)
Table Global CINV Existing and Pipeline Drugs Market Share Forecast by Type (2022-2027)
Table Global CINV Existing and Pipeline Drugs Sales Forecast by Application (2022-2027)
Table Global CINV Existing and Pipeline Drugs Market Share Forecast by Application (2022-2027)
Table Market Opportunities in Next Few Years
Table Market Risks Analysis
Table Market Drivers
Figure Porter's Five Forces Analysis
Table Macro Analysis of Upstream Markets
Table Key Players in Upstream Markets
Table Key Players of Upstream Markets
Table Key Raw Materials
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of CINV Existing and Pipeline Drugs
Table Macro Analysis of Down Markets
Table Key Players in Down Markets
Table Key Players of Downstream Markets
Figure Sales Channel
Figure North America CINV Existing and Pipeline Drugs Sales (K Units) Growth Rate Forecast (2021-2025)
Figure North America CINV Existing and Pipeline Drugs Revenue (Million US$) Growth Rate Forecast (2021-2025)
Figure Europe CINV Existing and Pipeline Drugs Sales (K Units) Growth Rate Forecast (2021-2025)
Figure Europe CINV Existing and Pipeline Drugs Revenue (Million US$) Growth Rate Forecast (2021-2025)
Figure Japan CINV Existing and Pipeline Drugs Production (K Units) Growth Rate Forecast (2021-2025)
Figure Japan CINV Existing and Pipeline Drugs Revenue (Million US$) Growth Rate Forecast (2021-2025)
Figure China CINV Existing and Pipeline Drugs Production (K Units) Growth Rate Forecast (2021-2025)
Figure China CINV Existing and Pipeline Drugs Revenue (Million US$) Growth Rate Forecast (2021-2025)
Figure Methodology/Research Approach
Figure Market Size Estimation
Figure Author List
GlaxoSmithKline
Helsinn
Heron Therapeutics